Precigen Reports Full Year 2024 Financial Results and Business Updates
Portfolio Pulse from
Precigen, Inc. reported its full-year 2024 financial results, highlighting a priority review by the FDA for its BLA for PRGN-2012, a treatment for recurrent respiratory papillomatosis, with a PDUFA date set for August 27, 2025. The company is preparing for a 2025 commercial launch and has extended its cash runway into 2026.
March 19, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen's financial results and FDA priority review for PRGN-2012 are significant. The PDUFA date is set for August 2025, and the company is preparing for a 2025 launch, with a cash runway into 2026.
The FDA's priority review and set PDUFA date for PRGN-2012 are positive indicators for Precigen, suggesting potential approval and market entry in 2025. The company's financial stability, with a cash runway into 2026, supports its readiness for commercialization.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100